Pursuant to Regulation 10(1A) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 02, 2025, Novartis India has submitted the Unaudited Financial Statements for the Quarter and half year ended September 30, 2025 along with the Limited Review Report (Annexure I & II) and other disclosures as required under the Integrated Filing (Financial) for the quarter and half-year ended September 30, 2025.
The above information is a part of company’s filings submitted to BSE.
